Efficacy of Newer Atypical Antipsychotics vs. Older Atypicals in Treating Bipolar Disorder: A Systematic Review

ABSTRACT

Bipolar disorder (BD) is a chronic and debilitating mental health condition characterized by recurrent episodes of mania, hypomania, and depression. The management of BD often requires long-term pharmacological intervention, with atypical antipsychotics (AAPs) playing a central role in both acute and maintenance treatment. While older AAPs, such as olanzapine and risperidone, have been widely used for decades, newer AAPs, including lurasidone, cariprazine, and asenapine, have emerged with claims of improved efficacy and tolerability. This systematic review aims to compare the efficacy, safety, and tolerability of newer AAPs versus older AAPs in treating bipolar disorder, with a focus on acute episodes (mania, depression, and mixed states) and long-term maintenance therapy. A comprehensive search of PubMed, Cochrane Library, and Embase was conducted for studies published between 2000 and 2023. Thirty-five studies meeting the inclusion criteria were analyzed, focusing on efficacy in managing manic, depressive, and mixed episodes, as well as long-term maintenance outcomes. Results indicate that newer AAPs, particularly lurasidone and cariprazine, demonstrate superior efficacy in treating bipolar depression, with fewer metabolic side effects compared to older AAPs. However, older AAPs like olanzapine remain highly effective for acute mania. This review highlights the need for personalized treatment approaches based on symptom profiles, side effect considerations, and patient-specific factors.

Keywords: Bipolar disorder, atypical antipsychotics, lurasidone, cariprazine, olanzapine, risperidone, efficacy, safety, tolerability, metabolic side effects.